Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

Figure 3

CT-322 reduces microvessel density in pancreatic cancer xenografts. MiaPaCa-2 tumor sections from animals treated with CT-322 or control were analyzed for microvessel density by immunohistochemistry using MECA-32. The mean (+/- SEM) number of blood vessels/high power field (total magnification, 400×) is displayed. The number of vessels in tumors from CT-322 treated animals was reduced compared to control (4.2 ± 4.7 versus 17.5 ± 4.7; 3 tumors per group, 3–5 high power fields per tumor; p = 0.001). Two representative pictures from each group are shown.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us